UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.376

Sortiert nach

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2016-11, Vol.375 (19), p.1823-1833

2016

Link zum Volltext

Verfügbarkeit prüfen

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Journal of clinical oncology, 2020-05, Vol.38 (14), p.1608-1632

2020

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

Clinical cancer research, 2018-12, Vol.24 (23), p.5841-5849

2018

Link zum Volltext

Verfügbarkeit prüfen

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline

Journal of clinical oncology, 2022-10, Vol.40 (28), p.3323-3343

2022

Link zum Volltext

Verfügbarkeit prüfen

Is cancer stage data missing completely at random? A report from a large population-based cohort of non-small cell lung cancer

Frontiers in oncology, 2023-04, Vol.13, p.1146053-1146053

2023

Link zum Volltext

Verfügbarkeit prüfen

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Journal of clinical oncology, 2019-03, Vol.37 (7), p.537-546

2019

Link zum Volltext

Verfügbarkeit prüfen

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

JTO clinical and research reports, 2021-08, Vol.2 (8), p.100205-100205, Article 100205

2021

Link zum Volltext

Verfügbarkeit prüfen

Quality of End-of-Life Care for People with Advanced Non-Small Cell Lung Cancer in Ontario: A Population-Based Study

Current oncology (Toronto), 2021-08, Vol.28 (5), p.3297-3315

2021

Link zum Volltext

Verfügbarkeit prüfen

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50

Journal of clinical oncology, 2021-07, Vol.39 (21), p.2339-2349

2021

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

Journal of clinical oncology, 2023-04, Vol.41 (11), p.1999-2006

2023

Link zum Volltext

Verfügbarkeit prüfen

COVID-19 and cancer: do we really know what we think we know?

Nature reviews. Clinical oncology, 2020-07, Vol.17 (7), p.386-388

2020

Link zum Volltext

Verfügbarkeit prüfen

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

The lancet oncology, 2017-12, Vol.18 (12), p.1600-1609

2017

Link zum Volltext

Verfügbarkeit prüfen

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Journal of clinical oncology, 2021-03, Vol.39 (9), p.1040-1091

2021

Link zum Volltext

Verfügbarkeit prüfen

Small Cell Lung Cancer in Light/Never Smokers - A Role for Molecular Testing?

Journal of the National Comprehensive Cancer Network, 2023-04, Vol.21 (4), p.336

2023

Link zum Volltext

Verfügbarkeit prüfen

Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomes in the General Population

Clinical genitourinary cancer, 2017-08, Vol.15 (4), p.e535-e541

2017

Link zum Volltext

Verfügbarkeit prüfen

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline

Journal of clinical oncology, 2022-10, Vol.40 (28), p.3310-3322

2022

Link zum Volltext

Verfügbarkeit prüfen

Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysis

European urology open science (Online), 2020-10, Vol.21, p.61-68

2020

Link zum Volltext

Verfügbarkeit prüfen

Treatment and Patient Selection for Patients with Metastatic Castration-resistant Prostate After Progression on Docetaxel and Abiraterone/Enzalutamide: When to Play Your CARD and When to Do Your PARP

European urology, 2021-08, Vol.80 (2), p.123-126

2021

Link zum Volltext

Verfügbarkeit prüfen

A Systematic Review and Meta-analysis of Dual Therapy in Patients With Advanced Renal Cell Carcinoma of Favourable Risk

Urology (Ridgewood, N.J.), 2021-11, Vol.157, p.8-14

2021

Link zum Volltext

Verfügbarkeit prüfen

Discussing Serious News Remotely: Navigating Difficult Conversations During a Pandemic

JCO oncology practice, 2020-07, Vol.16 (7), p.363-368

2020

Link zum Volltext

Verfügbarkeit prüfen

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2

Journal of clinical oncology, 2023-02, Vol.41 (5), p.e10-e20

2023

Link zum Volltext

Verfügbarkeit prüfen

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2

Journal of clinical oncology, 2023-02, Vol.41 (5), p.e1-e9

2023

Link zum Volltext

Verfügbarkeit prüfen

Progression-free survival as an end-point in solid tumours – Perspectives from clinical trials and clinical practice

European journal of cancer (1990), 2014-09, Vol.50 (13), p.2303-2308

2014

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Mental Health Service Utilization Among Survivors of Testicular Cancer: A Population-Based Cohort Study

Journal of clinical oncology, 2021-03, Vol.39 (7), p.779-786

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.376

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.290)
Mit Volltextzugriff
(1.225)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.047)
Life Sciences & Biomedicine
(872)
Humans
(666)
Female
(390)
Male
(353)
Middle Aged
(234)
Adult
(232)
Biological And Medical Sciences
(169)
Animals
(165)
Aged
(158)
General & Internal Medicine
(122)
Physical Sciences
(118)
Medical Sciences
(117)
Risk Factors
(105)
Biochemistry & Molecular Biology
(101)
Oncology
(100)
Medicine, General & Internal
(90)
Science & Technology - Other Topics
(89)
Treatment Outcome
(85)
Adolescent
(81)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

The New England Journal Of Medicine
(30)
Journal Of Clinical Oncology
(20)
Nature Genetics
(20)
Cell
(19)
The Journal Of Trauma And Acute Care Surgery
(19)
Nature Communications
(18)
Plos One
(18)
Cell Reports
(14)
Cancer Research
(13)
Nature
(13)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(13)

Menü

Weitere Dienste

Einstellungen

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline

Is cancer stage data missing completely at random? A report from a large population-based cohort of non-small cell lung cancer

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

Quality of End-of-Life Care for People with Advanced Non-Small Cell Lung Cancer in Ontario: A Population-Based Study

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50

Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

COVID-19 and cancer: do we really know what we think we know?

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Small Cell Lung Cancer in Light/Never Smokers - A Role for Molecular Testing?

Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomes in the General Population

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline

Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysis

Treatment and Patient Selection for Patients with Metastatic Castration-resistant Prostate After Progression on Docetaxel and Abiraterone/Enzalutamide: When to Play Your CARD and When to Do Your PARP

A Systematic Review and Meta-analysis of Dual Therapy in Patients With Advanced Renal Cell Carcinoma of Favourable Risk

Discussing Serious News Remotely: Navigating Difficult Conversations During a Pandemic

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2

Progression-free survival as an end-point in solid tumours – Perspectives from clinical trials and clinical practice

Long-Term Mental Health Service Utilization Among Survivors of Testicular Cancer: A Population-Based Cohort Study

Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial

Suchergebnisse filtern